Karin Jandeleit-Dahm

Summary

Affiliation: Baker Heart Research Institute
Country: Australia

Publications

  1. doi request reprint The AGE/RAGE axis in diabetes-accelerated atherosclerosis
    Karin Jandeleit-Dahm
    Albert Einstein Juvenile Diabetes Research Foundation Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Heart Research Institute, Melbourne, Victoria, Australia
    Clin Exp Pharmacol Physiol 35:329-34. 2008
  2. ncbi request reprint Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes
    Karin A M Jandeleit-Dahm
    Danielle Alberti Centre for Diabetes Complications, Vascular Division, Wynn Domain, Baker Heart Research Institute, Melbourne, Victoria, Australia
    J Hypertens 23:463-73. 2005
  3. ncbi request reprint Dual ACE/NEP inhibitors - more than playing the ACE card
    K A M Jandeleit-Dahm
    Baker Heart Research Institute, Danielle Alberti JDRF Centre for Diabetes Complications, Wynn Domain, Melbourne, Victoria, Australia
    J Hum Hypertens 20:478-81. 2006
  4. ncbi request reprint Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice
    Karin Jandeleit-Dahm
    The Baker Heart Research Institute, Vascular Division, Danielle Alberti Memorial Centre for Diabetes Complications, Melbourne, Australia
    J Hypertens 23:2071-82. 2005
  5. ncbi request reprint Hypertension and diabetes: role of the renin-angiotensin system
    Karin Jandeleit-Dahm
    Baker Heart Research Institute, Danielle Memorial Centre for Diabetes Complications, Wynn Domain, 75 Commercial Road, Melbourne 3004, Victoria, Australia
    Endocrinol Metab Clin North Am 35:469-90, vii. 2006
  6. pmc miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression
    Bo Wang
    JDRF Danielle Alberti Memorial Centre for Diabetes Complications, Melbourne, Australia
    Diabetes 60:280-7. 2011
  7. pmc Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis
    Bo Wang
    JDRF Danielle Alberti Memorial Centre for Diabetes Complications, Diabetes Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    J Am Soc Nephrol 23:252-65. 2012
  8. ncbi request reprint Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice
    Markus Lassila
    Baker Heart Research Institute, P O Box 6492, Commercial Road, Melbourne 8008, VIC 3004, Australia
    J Am Soc Nephrol 16:363-73. 2005
  9. ncbi request reprint The role of AGEs in cardiovascular disease
    Karin Jandeleit-Dahm
    JDRF Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Heart Research Institute, PO Box 6492 St Kilda Rd Central, Melbourne 8008, Australia
    Curr Pharm Des 14:979-86. 2008
  10. ncbi request reprint Cardiovascular disease: what's all the AGE/RAGE about?
    Drazenka P Barlovic
    Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Cardiovasc Hematol Disord Drug Targets 10:7-15. 2010

Collaborators

Detail Information

Publications17

  1. doi request reprint The AGE/RAGE axis in diabetes-accelerated atherosclerosis
    Karin Jandeleit-Dahm
    Albert Einstein Juvenile Diabetes Research Foundation Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Heart Research Institute, Melbourne, Victoria, Australia
    Clin Exp Pharmacol Physiol 35:329-34. 2008
    ..Based on these findings, RAGE could be a potential therapeutic target in combating inflammatory vascular diseases, including diabetes-associated atherosclerosis...
  2. ncbi request reprint Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes
    Karin A M Jandeleit-Dahm
    Danielle Alberti Centre for Diabetes Complications, Vascular Division, Wynn Domain, Baker Heart Research Institute, Melbourne, Victoria, Australia
    J Hypertens 23:463-73. 2005
    ....
  3. ncbi request reprint Dual ACE/NEP inhibitors - more than playing the ACE card
    K A M Jandeleit-Dahm
    Baker Heart Research Institute, Danielle Alberti JDRF Centre for Diabetes Complications, Wynn Domain, Melbourne, Victoria, Australia
    J Hum Hypertens 20:478-81. 2006
  4. ncbi request reprint Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice
    Karin Jandeleit-Dahm
    The Baker Heart Research Institute, Vascular Division, Danielle Alberti Memorial Centre for Diabetes Complications, Melbourne, Australia
    J Hypertens 23:2071-82. 2005
    ....
  5. ncbi request reprint Hypertension and diabetes: role of the renin-angiotensin system
    Karin Jandeleit-Dahm
    Baker Heart Research Institute, Danielle Memorial Centre for Diabetes Complications, Wynn Domain, 75 Commercial Road, Melbourne 3004, Victoria, Australia
    Endocrinol Metab Clin North Am 35:469-90, vii. 2006
    ..Agents that interrupt the RAAS confer end-organ protection in diabetes via hemodynamic and non-hemodynamic mechanisms. Trials are investigating the possible role of RAAS blockade in the prevention of type 2 diabetes...
  6. pmc miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression
    Bo Wang
    JDRF Danielle Alberti Memorial Centre for Diabetes Complications, Melbourne, Australia
    Diabetes 60:280-7. 2011
    ..Progressive fibrosis in the diabetic kidney is driven and sustained by a diverse range of profibrotic factors. This study examines the critical role of microRNAs (miRNAs) in the regulation of the key fibrotic mediators, TGF-β1 and TGF-β2...
  7. pmc Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis
    Bo Wang
    JDRF Danielle Alberti Memorial Centre for Diabetes Complications, Diabetes Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    J Am Soc Nephrol 23:252-65. 2012
    ..Pharmacologic modulation of these miRNAs may have therapeutic potential for progressive renal fibrosis...
  8. ncbi request reprint Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice
    Markus Lassila
    Baker Heart Research Institute, P O Box 6492, Commercial Road, Melbourne 8008, VIC 3004, Australia
    J Am Soc Nephrol 16:363-73. 2005
    ..Tyrosine kinase inhibition with imatinib seems to retard the development of experimental diabetic nephropathy...
  9. ncbi request reprint The role of AGEs in cardiovascular disease
    Karin Jandeleit-Dahm
    JDRF Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Heart Research Institute, PO Box 6492 St Kilda Rd Central, Melbourne 8008, Australia
    Curr Pharm Des 14:979-86. 2008
    ....
  10. ncbi request reprint Cardiovascular disease: what's all the AGE/RAGE about?
    Drazenka P Barlovic
    Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Cardiovasc Hematol Disord Drug Targets 10:7-15. 2010
    ....
  11. pmc E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta
    Bo Wang
    Juvenile Diabetes Research Foundation Danielle Alberti Memorial Centre for Diabetes Complications, Diabetes Division, Baker IDI Heart and Diabetes Institute, Victoria, Australia
    Diabetes 59:1794-802. 2010
    ..We investigated whether some of their effects may be mediated through changes in expression of certain microRNAs (miRNAs)...
  12. ncbi request reprint Antiproteinuric effect of RAS blockade: new mechanisms
    Markus Lassila
    Vascular Division, The Baker Heart Research Institute, Commercial Road, Melbourne 3004, Victoria, Australia
    Curr Hypertens Rep 6:383-92. 2004
    ..In this review, we analyze in detail the evidence for known and novel mechanisms considered to play important roles in mediating the antiproteinuric effect of RAS blockers, with a particular focus on diabetic nephropathy...
  13. ncbi request reprint Targets to retard the progression of diabetic nephropathy
    Mark E Cooper
    Danielle Alberti Memorial Centre for Diabetes Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia
    Kidney Int 68:1439-45. 2005
  14. ncbi request reprint Lipids and diabetic renal disease
    Mark E Cooper
    JDRF Danielle Alberti Memorial Centre for Diabetic Complications, Vascular Division Wynn Domain, Baker Heart Research Institute, 75 Commercial Road, Melbourne, Victoria 3004, Australia
    Curr Diab Rep 5:445-8. 2005
    ..Nevertheless, with the convincing antiatherosclerotic effects of these agents, including in the setting of diabetes, they should be widely administered in the diabetic population with or at risk for nephropathy...
  15. ncbi request reprint Hypertension and diabetes
    Karin Jandeleit-Dahm
    Department of Medicine, Repatriation Hospital, West Heidelberg, Victoria, Australia
    Curr Opin Nephrol Hypertens 11:221-8. 2002
    ..A number of recently published and ongoing trials are exploring the role of aggressive antihypertensive treatment with a range of antihypertensive drugs in diabetic subjects at risk of or with macrovascular disease...
  16. ncbi request reprint Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products
    Markus Lassila
    Danielle Alberti Memorial Centre for Diabetes Complications, Vascular Division, Wynn Domain, Baker Heart Research Institute, Melbourne, Victoria, Australia
    J Am Soc Nephrol 15:2125-38. 2004
    ..The accelerated renal injury that was observed in diabetic apo E-KO mice was attenuated by approaches that inhibit renal AGE accumulation...
  17. ncbi request reprint Advanced-glycation end products in insulin-resistant states
    Georgia Soldatos
    Baker Heart Research Institute, Commercial Road, Melbourne 3181, Victoria, Australia
    Curr Hypertens Rep 7:96-102. 2005
    ..In this review, we summarize the factors thought to be important in both the initiation and exacerbation of the insulin-resistant state, and directly examine the potential role of advanced-glycation end products in this process...